CERO: רווח נקי למניה (EPS TTM) CERo Therapeutics Holdings, Inc.

לוגו של חברה ציבורית CERo Therapeutics Holdings, Inc. (CERO)

The complexity of manual CAR-T therapy production limits the scalability of CERo Therapeutics (CERO), which impacts the rolling annual net income per share, where the figure remains around -34.85. Business success depends on scientific discoveries rather than macro cycles. Current development is driven by FDA requirements and investor support, which determine the pace of commercialization for innovative cancer treatments.

CERO (CERo Therapeutics) היסטוריית רווח נקי למניה אחת בשנים עשר החודשים האחרונים מ-21.02.2024 עד 08.11.2025

cero.bio - פילוחים אנליטיים ומדדי מפתח (CERO)

ניתוח כללי של החברה:CERo Therapeutics Holdings, Inc. (CERO)
מוצר סדרתי של CERo Therapeutics

Earnings per share (EPS TTM) reflects the trailing twelve-month income distributed across the total volume of issued securities. For CERo Therapeutics (CERO), this metric demonstrates the financial cost of developing robotic T-cell reprogramming systems. By analyzing the trailing twelve-month earnings per share trend, an investor assesses the efficiency of capital expenditures in the automation of oncology tests. This metric allows for the identification of the business's actual margin of safety. Steady growth of this indicator confirms the company's fundamental stability.

ניתוח חברות מתחרות